Rising to the challenges of rare disease treatment
We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

T-cell Image

Specialized BioTherapeutics Pipeline

Soligenix has specialized knowledge in the development of orphan and unmet medical need indications including preclinical, manufacturing, regulatory and clinical expertise.

PreclinicalPhase 1Phase 2Phase 3Market
SGX301 for Cutaneous T-Cell Lymphoma (CTCL)
Preclinical
Phase 1
Phase 2
Phase 3
Market
SGX942 for Oral Mucositis
Preclinical
Phase 1
Phase 2
Phase 3
Market
SGX203 for Pediatric Crohn’s Disease
Preclinical
Phase 1
Phase 2
Phase 3
Market
SGX201 for Radiation Enteritis
Preclinical
Phase 1
Phase 2
Phase 3
Market

Orphan and/or Fast Track Designation

Denotes funding in whole or in part by NIH, BARDA and/or FDA.

Public Health Solutions Pipeline

Soligenix has a number of Public Health programs, funded entirely by government grants and contracts, which focus on infectious disease and biodefense applications, including our most advanced vaccination program to prevent ricin poisoning.

Proof-of-ConceptINDPhase 1Phase 2/3Market
RiVax® to Prevent Ricin Poisoning
Proof-of-Concept
IND
Phase 1
Phase 2/3
Market
OrbeShield® for Acute Radiation Syndrome
Proof-of-Concept
IND
Phase 1
Phase 2/3
Market
SGX943 for Infectious Disease
Proof-of-Concept
IND
Phase 1
Phase 2/3
Market

Orphan and/or Fast Track Designation

Denotes funding in whole or in part by NIH, BARDA and/or FDA.
Papers and chars with medical data

CEO3in60 Video

Soligenix President & CEO Dr. Christopher J. Schaber provides 3 reasons you should invest in the Company in this brief video

Want to stay up to date with our latest news?

Subscribe To Our Newsletter